New guidelines for clinical evaluation of anti-cancer drugs in Japan

被引：0

作者：

Minami, Hironobu ^{[1
]}

机构：

[1] Kobe Univ, Med Oncol Hematol, Grad Sch Med, Kobe, Hyogo, Japan

来源：

关键词：

D O I：

10.1016/j.annonc.2022.05.443

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SY07-1

引用

下载

页码：S430 / S430

页数：1

共 50 条

[31] HANDLING ANTI-CANCER DRUGS
不详
LANCET, 1983, 1 (8323): : 543 - 543
[32] Anti-cancer drugs for cardioprotection
Wu, Nan
Xie, Yizhen
Yang, Burton B.
CELL CYCLE, 2017, 16 (02) : 155 - 156
[33] TESTING ANTI-CANCER DRUGS
BERENBAUM, MC
SHEARD, CE
LANCET, 1972, 1 (7760): : 1116 - +
[34] Improved anti-cancer drugs
Barden, D
DALTON TRANSACTIONS, 2005, (11) : C42 - C42
[35] Improved anti-cancer drugs
Barden, D
CHEMISTRY WORLD, 2005, 2 (06): : 20 - 20
[36] TESTING ANTI-CANCER DRUGS
MITCHELL, JS
DAWSON, MPA
DENDY, PP
WHEELER, TK
LANCET, 1972, 1 (7757): : 955 - &
[37] Application to anti-cancer drugs
Olejniczak, K.
TOXICOLOGY LETTERS, 2011, 205 : S2 - S2
[38] Proteomics of anti-cancer drugs
Kovarova, H.
Martinkova, J.
Hrabakova, R.
Skalnikova, H.
Novak, P.
Hajduch, M.
Gadher, S. J.
FEBS JOURNAL, 2009, 276 : 84 - 84
[39] METABOLISM OF ANTI-CANCER DRUGS
CONNORS, TA
BIOCHIMIE, 1978, 60 (09) : 1070 - 1070
[40] Anti-cancer drugs - Preface
Bergmann-Leitner, E
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (25)